Eradication of enterococcus faecalis by phage therapy in chronic bacterial prostatitis - Case report

Folia Microbiologica

Volumn 54, Issue 5, 2009, Pages 457-461

  Letkiewicz, S ^a,b   Miedzybrodzki, R ^b   Fortuna, W ^b   Weber Dabrowska, B ^b   Gorskib A ^b  

^a Urological and Andrological Clinic UROGEN   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS;

ADULT; ARTICLE; BACTERIOPHAGE; BIOLOGICAL THERAPY; CASE REPORT; CHEMISTRY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; PHYSIOLOGY; PROSTATITIS; VIROLOGY;

ADULT; BACTERIOPHAGES; BIOLOGICAL THERAPY; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; PROSTATITIS;

EID: 74949122775     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12223-009-0064-z     Document Type: Article

References (25)

1. ARIAS C.A., MURRAY B.E.: Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. New EnglJ.Med. 360, 439-443 (2009).
2. BENWAY B.M., MOON T.D.: Bacterial prostatitis. Urol.Clin.N.Am. 35,23-32 (2008).
3. BISWAS B., ADHYA S., WASHART P., PAUL B., TROSTEL A.N., POWELL B., CARLTON R., MERRIL C.R.: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect.Immun. 70,204-210 (2002).
4. DRAHOVSKÁ H., SLOBODNÍKOVÁ L., KocÍ NCOVÁ D., SEMAN M., KONČEKOVÁ R., TRUPL J., TURŇA J.: Antibiotic resistance and virulence factors among clinical and food enterococci isolated in Slovakia. Folia Microbiol. 49, 763-768 (2004).
5. DWORNICZEK E., KUZKO K., MRÓZ E., WOJCIECH LŁ., ADAMSKI R., SOBIESZCZAŃSKA B., SENIUK A.: Virulence factors and in vitro adherence of Enterococcus strains to urinary catheters. Folia Microbiol. 48, 671-678 (2003).
6. FREITAG T., SQUIRES R.A., SCHMID J.: Naturally occurring bacteriophages lyse a large proportion of canine and feline uropathogenic Escherichia coli isolates in vitro. Res. Vet.Sci. 85, 1-7 (2008).
7. GÓRSKI A., MIEDZYBRODZKI R., BORYSOWSKI J., WEBER-DABROWSKA B., LOBOCKA M., FORTUNA W., LETKIEWICZ S., ZIMECKI M., FILBY G.: Bacteriophage therapy for the treatment of infections. Curr.Opin.Investig.Drugs 10, 766-774 (2009).
8. HOFFMANN M.: Tierversuche zur Schleimhautpassage und Resorptionsviramie von T3-Phagen nach oraler, trachealer und rektaler Gabe. Z.Bakteriol.Med.-Hyg. Bakteriol. Virusforsch.Parasitol. 198, 371-390 (1965).
9. Hu W.L., ZHONG S.Z., HE H.X.: Treatment of chronic bacterial prostatitis with amikacin through anal submucosal injection. Asian J.Androl. 4, 163-167 (2002).
10. KURZEPA A., DABROWSKA K., ŚWTTALA-JELEŃ A., GÓRSKI A.: Molecular modification of T4 bacteriophage proteins and its potential application. Folia Microbiol. 54, 5-15 (2009).
11. LANG L.H.: FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 131, 1370 (2006).
12. LITWIN M.S., MCNAUGHTON-COLLINS M., FOWLER F.J. Jr., NICKEL J.C., CALHOUN E.A., PONTARI M.A., ALEXANDER R.B., FAR-RAR J.T., O'LEARY M.P.: The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J.Urol. 162, 369-375 (1999).
13. MIEDZYBRODZKI R., ŚwiTALA-JELEŃ K., FORTUNA W., WEBER-DABROWSKA B., PRZERWA A., KURZEPA A., LŁUSIAK-SZELACHOWSKA M., DABROWSKA K., BORATYŃSKI J., SYPER D., LŁUGOWSKI C., POŹNIAK G., GÓRSKI A.: Bacteriophage inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. 131,233-242 (2008).
14. MIEDZYBRODZKI R., FORTUNA W., WEBER-DABROWSKA B., GÓRSKI A.: A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin.Exp.Med. (2009); doi: 1o.10O7/s10238-009-O044-2.
15. VAN NIEUWKOOP C., VISSER L.G., GROENEVELD J.H., KuIJPER E.J.: Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteremia successfully treated with moxifloxacin. J.Infect. 56, 155-156 (2008).
16. NIGUTOvÁ K., ŠTYRIAK I., JAVORSKÝ P., PRISTAŠ P.: Partial characterization of Enterococcus faecalis bacteriophage F4. Folia Microbiol. 53, 234-236 (2008).
17. NISHIKAWA H., YASUDA M., UCHIYAMA J., RASHEL M., MAEDA Y., TAKEMURA I., SUGIHARA S., UJIHARA T., SHIMIZU Y., SHUIN T., MATSUZAKI S.: T-Even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch. Virol. 153, 507-515(2008).
18. OmniLytics: AgriPhageTM product info; http://www.Comnilytics.cani/ products/agriphage/agriphage-info/agriphage-overview.html (accessed 22.5.2009).
19. PRONK M.J., PELGER R.C., BARANSKI A.G., VAN DAM A., AREND S.M.: Cure of chronic prostatitis presumably due to Enterococcus spp. and Gram-negative bacteria. EurJ.Clin.Microbiol.Infect.Dis. 25,270-271 (2006).
20. SCHAEFFER A.J.: Epidemiology and demographics of prostatitis. Eur.Urol. 2 (Suppl.), 5-10 (2003).
21. SCHLEGEL P.N., CHANG T.S., MARSHALL F.F.: Antibiotics: potential hazards to male fertility. Fertil.Steril. 55, 235-242 (1991).
22. SHAFIK A., MOHI-EL-DIN M.: A new concept of the anatomy of the anal sphincter mechanism and the physiology of defecation - XXIV. Hemorrhoidal venous plexuses: anatomy and role in hemorrhoids. Coloproctology 7, 291-296 (1985).
23. ŚLOPEK S., DURLAKOWA I., WEBER-DABROWSKA B., KUCHAREWICZ-KRUKOWSKA A., DABROWSKI M., BISIKIEWICZ R.: Results of bacteriophage treatment of suppurative bacterial infections - I. General evaluation of the results. Arch.Immunot.Ther.Exp. 31, 267-291(1983).
24. WAGENLEHNER F.M.E., DIEMER T., NABER K.G., WEIDNER W.: Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. Andrologia 40, 100-104 (2008).
25. ZHOU J.F., XIAO W.Q., ZHENG Y.C., DONG J., ZHANG S.M.: Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis. Asian J.Androl. 8, 317-323 (2006).